Genetic control of the circulating concentration of transforming growth factor type β1

被引:654
作者
Grainger, DJ
Heathcote, K
Chiano, M
Snieder, H
Kemp, PR
Metcalfe, JC
Carter, ND
Spector, TD
机构
[1] St Thomas Hosp, Twin Res & Genet Epidemil Unit, London SE1 7EH, England
[2] Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England
[3] Univ Cambridge, Dept Biochem, Cambridge CB2 2QW, England
[4] Gemini Res Ltd, Cambridge CB4 4GH, England
[5] St Georges Hosp, Sch Med, Dept Med Genet, London S17 0RE, England
基金
英国惠康基金;
关键词
D O I
10.1093/hmg/8.1.93
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The concentration of transforming growth factor beta (TGF-beta) in plasma has been correlated with the development of several diseases, including atherosclerosis and certain forms of cancer. However, the mechanisms that control the concentration of TGF-beta in plasma are poorly understood. In a study of 170 pairs of female twins (average age 57.7 years) we show that the concentration of active plus acid-activatable latent TGF-beta 1 [(a+l) TGF-beta therefore is predominantly under genetic control (heritability estimate 0.54). Single strand conformation polymorphism (SSCP) mapping of the TGF-beta 1 gene promoter has identified two single base substitution polymorphisms. The two polymorphisms (G-->A at position -800 bp and C-->T at position -509 bp) are in linkage disequilibrium (correlation coefficient Delta = 0.215, P < 0.01). The C-509T polymorphism is significantly associated with the plasma concentration of (a+l) TGF-beta 1, explaining 8.2% of the additive genetic variance of (a+l) TGF-beta 1 concentration. It is therefore possible that predisposition to atherosclerosis, bone diseases or various forms of cancer may be correlated with the presence of particular alleles at the TGFB1 locus.
引用
收藏
页码:93 / 97
页数:5
相关论文
共 36 条
[1]   TRANSFORMING GROWTH-FACTOR-BETA AS A PREDICTOR OF LIVER AND LUNG FIBROSIS AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR ADVANCED BREAST-CANCER [J].
ANSCHER, MS ;
PETERS, WP ;
REISENBICHLER, H ;
PETROS, WP ;
JIRTLE, RL .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (22) :1592-1598
[2]   ANTI-TRANSFORMING GROWTH-FACTOR (TGF)-BETA ANTIBODIES INHIBIT BREAST-CANCER CELL TUMORIGENICITY AND INCREASE MOUSE SPLEEN NATURAL-KILLER-CELL ACTIVITY - IMPLICATIONS FOR A POSSIBLE ROLE OF TUMOR-CELL HOST TGF-BETA INTERACTIONS IN HUMAN BREAST-CANCER PROGRESSION [J].
ARTEAGA, CL ;
HURD, SD ;
WINNIER, AR ;
JOHNSON, MD ;
FENDLY, BM ;
FORBES, JT .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (06) :2569-2576
[3]   Polymorphisms of the transforming growth factor-beta 1 gene in relation to myocardial infarction and blood pressure - The Etude Cas-Temoin de l'Infarctus du Myocarde (ECTIM) Study [J].
Cambien, F ;
Ricard, S ;
Troesch, A ;
Mallet, C ;
Generenaz, L ;
Evans, A ;
Arveiler, D ;
Luc, G ;
Ruidavets, JB ;
Poirier, O .
HYPERTENSION, 1996, 28 (05) :881-887
[4]  
CHIANO MN, 1996, P GEN AN WORKSH GAW1
[5]  
CUI W, 1994, CANCER RES, V54, P5831
[6]   TGF beta 1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice [J].
Cui, W ;
Fowlis, DJ ;
Bryson, S ;
Duffie, E ;
Ireland, H ;
Balmain, A ;
Akhurst, RJ .
CELL, 1996, 86 (04) :531-542
[7]  
Danielpour D, 1996, J CELL PHYSIOL, V166, P231, DOI 10.1002/(SICI)1097-4652(199601)166:1<231::AID-JCP24>3.0.CO
[8]  
2-G
[9]   EVIDENCE FOR DIFFERENTIAL REGULATION OF TGF-BETA-1 AND TGF-BETA-2 EXPRESSION INVIVO BY SANDWICH ENZYME-LINKED IMMUNOSORBENT ASSAYS [J].
DANIELPOUR, D ;
KIM, KY ;
DART, LL ;
WATANABE, S ;
ROBERTS, AB ;
SPORN, MB .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1990, 593 :300-302
[10]   THE SERUM CONCENTRATION OF ACTIVE TRANSFORMING GROWTH-FACTOR-BETA IS SEVERELY DEPRESSED IN ADVANCED ATHEROSCLEROSIS [J].
GRAINGER, DJ ;
KEMP, BR ;
METCALFE, JC ;
LIU, AC ;
LAWN, RM ;
WILLIAMS, NR ;
GRACE, AA ;
SCHOFIELD, PM ;
CHAUHAN, A .
NATURE MEDICINE, 1995, 1 (01) :74-79